Living Cell Technologies Chairman Sends a Letter to Shareholders

Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.